Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 50% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 10.0% — below-average profitability
- Revenue growing at 6% annually
DOLBY LABORATORIES, INC. (DLB) is a Financial Services company operating in Patent Owners & Lessors, listed on the NYSE , with a market capitalisation of $5.8 billion . Key value metrics: P/E ratio 22.6, P/B ratio 2.25, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
DOLBY LABORATORIES, INC. — Fundamental Analysis Summary
DOLBY LABORATORIES, INC. (DLB) is currently trading 50% above its Graham Number of $40.73, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 22.6x.
On financial health, DLB shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 10.0% (sector average: 5.8%), and minimal leverage with a debt-to-equity ratio of 0.23.
StockPik's composite Value Score for DLB is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DLB reports a high gross margin of 88.2% (sector average: 9.2%) and a strong operating margin of 21.4%.
DLB shows revenue growing at 6% year-over-year, with earnings declining at 3%.
DLB pays a modest dividend yield of 2.2%.